{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:16:42Z","timestamp":1780525002944,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GlaxoSmithKline Biological SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The efficacy of the four-component 4CMenB vaccine is measured through the serum bactericidal antibody (SBA) assay on four meningococcal B (MenB) indicator strains. However, they are not epidemiologically relevant for disease, thus the real-world persistence of 4CMenB protection remains uncertain. Several mathematical models of waning immunity were fitted on longitudinal SBA data from persistence studies in adolescents, with up to eight years follow-up after 4CMenB priming vaccination. The best model was used to predict protection from indicator strains. MenB typing data from the United States were used to integrate antigen-level curves and predict the persistence of protection from real-world MenB strains, considering synergies between antigens. Models show that protection and its evolution varied by antigen and that 4CMenB likely elicits antibody-producing long-lived plasma cells. 4CMenB protection from real-world MenB disease persisted at 61.5% four years post-priming and 70.5% four years post-booster. This evidence could support decision-making on adolescent immunization programs.<\/jats:p>","DOI":"10.1038\/s41541-024-01025-5","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T09:34:40Z","timestamp":1733132080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Modeling the persistence of 4CMenB vaccine protection against real world meningococcal B disease in adolescents"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-068X","authenticated-orcid":false,"given":"Lorenzo","family":"Argante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavia","family":"Prunas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duccio","family":"Medini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Ypma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"1025_CR1","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","volume":"369","author":"DS Stephens","year":"2007","unstructured":"Stephens, D. S., Greenwood, B. & Brandtzaeg, P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet (Lond., Engl.) 369, 2196\u20132210 (2007).","journal-title":"Lancet (Lond., Engl.)"},{"key":"1025_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/14760584.2019.1557520","volume":"18","author":"R Acevedo","year":"2019","unstructured":"Acevedo, R. et al. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev. Vaccines 18, 15\u201330 (2019).","journal-title":"Expert Rev. Vaccines"},{"key":"1025_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/21645515.2018.1528831","volume":"15","author":"C Burman","year":"2019","unstructured":"Burman, C. et al. Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination. Hum. Vaccines Immunother. 15, 459\u2013469 (2019).","journal-title":"Hum. Vaccines Immunother."},{"key":"1025_CR4","unstructured":"Australian Government. Australian Immunisation Handbook - Meningococcal disease: Recommendations. https:\/\/immunisationhandbook.health.gov.au\/contents\/vaccine-preventable-diseases\/meningococcal-disease#recommendations (2022)."},{"key":"1025_CR5","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics - Bexsero. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bexsero (2023)."},{"key":"1025_CR6","unstructured":"Food and Drug Administration (FDA). Package insert - Bexsero. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/bexsero (2022)."},{"key":"1025_CR7","doi-asserted-by":"publisher","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","volume":"30","author":"D Serruto","year":"2012","unstructured":"Serruto, D., Bottomley, M. J., Ram, S., Giuliani, M. M. & Rappuoli, R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens. Vaccine 30, B87\u2013B97 (2012).","journal-title":"Vaccine"},{"key":"1025_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1600-065X.2010.00912.x","volume":"236","author":"IJ Amanna","year":"2010","unstructured":"Amanna, I. J. & Slifka, M. K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol. Rev. 236, 125\u2013138 (2010).","journal-title":"Immunol. Rev."},{"key":"1025_CR9","doi-asserted-by":"publisher","first-page":"e2006601","DOI":"10.1371\/journal.pbio.2006601","volume":"16","author":"A Antia","year":"2018","unstructured":"Antia, A. et al. Heterogeneity and longevity of antibody memory to viruses and vaccines. PLoS Biol. 16, e2006601 (2018).","journal-title":"PLoS Biol."},{"key":"1025_CR10","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider, I., Gotschlich, E. C. & Artenstein, M. S. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129, 1307\u20131326 (1969).","journal-title":"J. Exp. Med."},{"key":"1025_CR11","doi-asserted-by":"publisher","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","volume":"27","author":"CE Frasch","year":"2009","unstructured":"Frasch, C. E., Borrow, R. & Donnelly, J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27, B112\u2013B116 (2009).","journal-title":"Vaccine"},{"key":"1025_CR12","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1016\/j.vaccine.2015.06.103","volume":"33","author":"KP Perrett","year":"2015","unstructured":"Perrett, K. P. et al. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine 33, 5217\u20135224 (2015).","journal-title":"Vaccine"},{"key":"1025_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","volume":"379","author":"ME Santolaya","year":"2012","unstructured":"Santolaya, M. E. et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study. Lancet (Lond. Engl.) 379, 617\u2013624 (2012).","journal-title":"Lancet (Lond. Engl.)"},{"key":"1025_CR14","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.4161\/hv.25505","volume":"9","author":"ME Santolaya","year":"2013","unstructured":"Santolaya, M. E. et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum. Vaccines Immunotherap. 9, 2304\u20132310 (2013).","journal-title":"Hum. Vaccines Immunotherap."},{"key":"1025_CR15","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.vaccine.2018.12.059","volume":"37","author":"T Nolan","year":"2019","unstructured":"Nolan, T. et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine 37, 1209\u20131218 (2019).","journal-title":"Vaccine"},{"key":"1025_CR16","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1016\/j.vaccine.2015.03.001","volume":"33","author":"SL Block","year":"2015","unstructured":"Block, S. L. et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. Vaccine 33, 2500\u20132510 (2015).","journal-title":"Vaccine"},{"key":"1025_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/INF.0000000000001896","volume":"37","author":"L Szenborn","year":"2018","unstructured":"Szenborn, L. et al. Immune responses to booster vaccination with meningococcal ABCWY vaccine after primary vaccination with either investigational or licensed vaccines: a phase 2 randomized study. Pediatr. Infect. Dis. J. 37, 475\u2013482 (2018).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"1025_CR18","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","volume":"31","author":"G Frosi","year":"2013","unstructured":"Frosi, G. et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 31, 4968\u20134974 (2013).","journal-title":"Vaccine"},{"key":"1025_CR19","doi-asserted-by":"publisher","first-page":"19490","DOI":"10.1073\/pnas.1013758107","volume":"107","author":"J Donnelly","year":"2010","unstructured":"Donnelly, J. et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl. Acad. Sci. USA 107, 19490\u201319495 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1025_CR20","doi-asserted-by":"publisher","first-page":"e00261","DOI":"10.1128\/mSphere.00261-17","volume":"2","author":"G Rajam","year":"2017","unstructured":"Rajam, G. et al. Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States. mSphere 2, e00261\u201317 (2017).","journal-title":"mSphere"},{"key":"1025_CR21","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1016\/j.vaccine.2007.02.069","volume":"25","author":"C Fraser","year":"2007","unstructured":"Fraser, C. et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25, 4324\u20134333 (2007).","journal-title":"Vaccine"},{"key":"1025_CR22","doi-asserted-by":"publisher","first-page":"6309","DOI":"10.1016\/j.vaccine.2016.10.049","volume":"34","author":"MB van Ravenhorst","year":"2016","unstructured":"van Ravenhorst, M. B. et al. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination. Vaccine 34, 6309\u20136315 (2016).","journal-title":"Vaccine"},{"key":"1025_CR23","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1016\/j.vaccine.2017.05.065","volume":"35","author":"J Sevestre","year":"2017","unstructured":"Sevestre, J. et al. Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: lessons of the Normandy campaign. Vaccine 35, 4029\u20134033 (2017).","journal-title":"Vaccine"},{"key":"1025_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1586\/erv.11.10","volume":"10","author":"H Sanders","year":"2011","unstructured":"Sanders, H. & Feavers, I. M. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines. Expert Rev. Vaccines 10, 323\u2013334 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"1025_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0642-2","volume":"14","author":"L Argante","year":"2016","unstructured":"Argante, L., Tizzoni, M. & Medini, D. Fast and accurate dynamic estimation of field effectiveness of meningococcal vaccines. BMC Med 14, 98 (2016).","journal-title":"BMC Med"},{"key":"1025_CR26","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1016\/j.vaccine.2020.08.007","volume":"38","author":"E Beck","year":"2020","unstructured":"Beck, E. et al. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England. Vaccine 38, 7558\u20137568 (2020).","journal-title":"Vaccine"},{"key":"1025_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06906-x","volume":"21","author":"L Argante","year":"2021","unstructured":"Argante, L., Abbing-Karahagopian, V., Vadivelu, K., Rappuoli, R. & Medini, D. A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model. BMC Infect. Dis. 21, 1244 (2021).","journal-title":"BMC Infect. Dis."},{"key":"1025_CR28","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/aje\/kwab266","volume":"191","author":"O Prunas","year":"2022","unstructured":"Prunas, O., Weinberger, D. M., Medini, D., Tizzoni, M. & Argante, L. Evaluating the impact of meningococcal vaccines with synthetic controls. Am. J. Epidemiol. 191, 724\u2013734 (2022).","journal-title":"Am. J. Epidemiol."},{"key":"1025_CR29","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1016\/j.vaccine.2023.02.078","volume":"41","author":"B Cai","year":"2023","unstructured":"Cai, B., Peyrani, P., Beeslaar, J., Burman, C. & Balmer, P. Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp. Vaccine 41, 2729\u20132733 (2023).","journal-title":"Vaccine"},{"key":"1025_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.epidem.2016.04.001","volume":"16","author":"PFM Teunis","year":"2016","unstructured":"Teunis, P. F. M., van Eijkeren, J. C. H., de Graaf, W. F., Marinovi\u0107, A. B. & Kretzschmar, M. E. E. Linking the seroresponse to infection to within-host heterogeneity in antibody production. Epidemics 16, 33\u201339 (2016).","journal-title":"Epidemics"},{"key":"1025_CR31","doi-asserted-by":"publisher","first-page":"e1002418","DOI":"10.1371\/journal.pcbi.1002418","volume":"8","author":"M Andraud","year":"2012","unstructured":"Andraud, M. et al. Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis a virus. PLoS Comput. Biol. 8, e1002418 (2012).","journal-title":"PLoS Comput. Biol."},{"key":"1025_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/biostatistics\/1.4.355","volume":"1","author":"H Jacqmin-Gadda","year":"2000","unstructured":"Jacqmin-Gadda, H., Thi\u00e9baut, R., Ch\u00eane, G. & Commenges, D. Analysis of left-censored longitudinal data with application to viral load in HIV infection. Biostatistics 1, 355\u2013368 (2000).","journal-title":"Biostatistics"},{"key":"1025_CR33","doi-asserted-by":"publisher","DOI":"10.7717\/peerj-cs.55","volume":"2","author":"J Salvatier","year":"2016","unstructured":"Salvatier, J., Wiecki, T. & Fonnesbeck, C. Probabilistic programming in python using PyMC. Peer J. Comput. Sci. 2, e55 (2016).","journal-title":"Peer J. Comput. Sci."},{"key":"1025_CR34","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s11222-016-9696-4","volume":"27","author":"A Vehtari","year":"2017","unstructured":"Vehtari, A., Gelman, A. & Gabry, J. Practical Bayesian model evaluation using leave-one-out cross-validation and WAIC. Stat. Comput. 27, 1413\u20131432 (2017).","journal-title":"Stat. Comput."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01025-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01025-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01025-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T10:03:33Z","timestamp":1734084213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01025-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1025"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01025-5","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The wrong Supplementary file was originally published with this article (with the incorrect title and affiliation numbering); it has now been replaced with the correct file.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.A. and E.Y. are employed by GSK. O.P. was enrolled in a PhD program from the University of Torino with funding from GSK during the initial phase of the study (period 2017\u20132020). D.M. was employed by GSK at the time of the study. The authors declare no other financial and non-financial relationships and activities.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"239"}}